- Home
- VGI vs IMUX Comparison
VGI vs IMUX Comparison
Compare VGI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | IMUX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.0M | 75.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | VGI | IMUX |
|---|---|---|
| Price | $7.33 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 45.4K | ★ 2.9M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $0.51 |
| 52 Week High | $8.09 | $1.51 |
Technical Indicators
Market Signals| Indicator | VGI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 24.54 | 56.81 |
| Support Level | N/A | $0.64 |
| Resistance Level | $7.97 | $1.51 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 9.69 | 27.78 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.